Navegando por Assunto "Perda de Peso"

Agora exibindo 1 - 2 de 2

Avaliação da resposta ao tratamento de obesidade em pacientes atendidos no Centro de Especialidades Médicas do CESUPA
(Centro Universitário do Estado do Pará, 2020) Alves, Beatriz Ribeiro; Cavalli, Lorena Silva; Cavallero, Mônica Ribeiro Maués
Introduction: Obesity is one of the major public health problems in the world, associated with reduced quality of life and life expectancy, as well as outcomes of other diseases. Pharmacological treatment of obesity is indicated when the patient has a BMI greater than or equal to 30 kg/m2 or when the individual has diseases associated with overweight with BMI equal to or greater than 25 kg/m2 in situations that behavioral changes were unsuccessful. Thus, conduction after identification of risk or confirmed diagnosis is prevention/intervention, including a quali-quantitatively adequate diet, as well as the practice of physical activity, multiprofessional care and adequate introduction of medication. Objective: To evaluate the response of weight loss in patients seen at the Obesity Outpatient Clinic of the Center for Medical Specialties of the University Center of the State of Pará. Methodology: A cross-sectional, quantitative and descriptive study of exploratory documental analysis was carried out at the University Center of the State of Pará (CESUPA) from August 2016 to August 2020. Results: Seventyseven patients were evaluated, of which 94.8% (n=73) were female soldering with a mean age of 43 years. The mean abdominal circumference (WC) at the beginning of treatment was 108.9cm and 103.7cm at the end of 1 year. Of the 77 patients evaluated, 81% used sibutramine, 44% used Orlistate, 32% from Topiramate, 13% used Sertraline and 22% fluoxetine. Among the 62 patients who used sibutramine, 29% had weight loss in 1 year greater than 10%, mainly associated with side effects such as dry mouth (74.2%) followed by constipation (35.5%). The use of orlistat was performed by 34 patients, and of these, 50% lost less than 5% in 1 year, and 50%, between 5 and 10% in weight. Of these, 46.2% presented stathertomy, being the main adverse effect. Conclusion: Sibutramine and orlistat stand out among the drugs approved for the global treatment of obesity due to the large number of investigations performed and the results obtained that demonstrate safety and efficacy. Sibutramine is the most commonly used drug in the treatment of obesity, due to its important efficacy and also due to financial issues, being its cost more affordable when compared to orlistat. Despite the satisfactory results with these drugs, so far demonstrated, the use of pharmacotherapy alone will not be enough to stop the advances of the obesity epidemic, and one should take into account the lifestyle with behavioral changes that include a healthy diet allied to the practice of physical activity.
O uso do Ozempic® off-label para fins estéticos: uma revisão de literatura
(Centro Universitário do Estado do Pará, 2025-06-17) Cruz, Ana Maria Silva Pardim da; Dantas, Gabriela Sousa Estrela; Rodrigues, Lorena de Cássia Fonseca; Silva, Paula Sousa da; Gomes, Jocileide de Sousa; https://lattes.cnpq.br/5419005361047694; https://lattes.cnpq.br/3929566584203932; Marucia Fernandes; http://lattes.cnpq.br/6797149526961226; Costa, Larissa Kelly Cunha; https://lattes.cnpq.br/8153849890032961
INTRODUCTION: Nowadays, many people resort to the use of medications to achieve the perfect body, considered ideal by society, trying to lose weight quickly and satisfactorily. Although these medications can offer short-term results, their indiscriminate use can cause harm to health, depending on the clinical conditions of each individual, in addition to causing several side effects. These medications act in three main ways: inhibiting appetite, increasing the feeling of satiety or preventing the absorption of consumed fat. Therefore, their use should be done carefully and under specialized guidance (Andrade, et al., 2019; Lima, 2020). Considering that Ozempic® has an effect on weight loss, its misuse without clinical monitoring can lead to consequences. Although it is proposed to control type 2 diabetes, its use in non-diabetic people can lead to episodes of hypoglycemia, especially when combined with restricted diets, and gastrointestinal problems such as nausea, vomiting and diarrhea. OBJECTIVES: To identify studies/research in national and international literature that address the use of Ozempic®, produced from 2020 to 2025. To identify the profile of publications verifying the benefits and harms of Ozempic® (semaglutide) selected by year in the database. To discuss the publications to understand the point of view in the literature on the debate of the harms and benefits of Ozempic® (semaglutide) in order to encourage discussion on the use of this medication. METHODOLOGY: Based on the objectives outlined, a literature review and a descriptive, exploratory research with a mixed approach (qualitative and quantitative) were carried out. RESULTS: The search carried out in the databases resulted in the initial identification of 152 articles related to the study theme. However, after applying the previously established inclusion and exclusion criteria, 23 articles were selected that presented citations directly related to the object of study, including the terms "Ozempic", "weight loss", "aesthetics", "obesity", "weight loss", "semaglutide", "off-label use" and "weight reduction". The journals found show a distribution of publications concentrated mainly in the most recent years. FINAL CONSIDERATIONS: In this study, it was possible to analyze the off-label use of Ozempic ® (semaglutide) for aesthetic purposes, highlighting mainly its impacts on public health. In this sense, the study reinforces the relevance of promoting health education and guidance by qualified professionals on the risks and benefits involved, in order to reduce possible complications and encourage a more responsible and safe use of the drug.